Health-related quality-of-life evaluation of crohn disease patients after receiving natalizumab therapy

Gastroenterology Nursing

Volumn 32, Issue 5, 2009, Pages 327-339

  Dudley Brown, Sharon ^a   Nag, Arpita ^b   Cullinan, Cory ^c   Ayers, Mary ^d   Hass, Steve ^e   Panjabi, Sumeet ^e  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b College of Pharmacy ^*  (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^e ELAN PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; NATALIZUMAB; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ARTICLE; BIOLOGICAL THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; FEMALE; HUMAN; MALE; NURSING; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; BIOLOGICAL THERAPY; CROHN DISEASE; FEMALE; HUMANS; MALE; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 70350346073     PISSN: 1042895X     EISSN: 15389766     Source Type: Journal    
DOI: 10.1097/SGA.0b013e3181bb1484     Document Type: Article

References (45)

1. Adalimumab [prescribing information]. 2008). Abbott Park, IL: Abbott Laboratories. Retrieved August 15 2008, from http://www.rxabbott. com/pdf/humira.pdf
2. Ardizzone, S., Puttini, P. S., Cassinotti, A., & Porro, G. (2008). Extraintestinal manifestations of inflammatory bowel disease. Digestive & Liver Disease, 40(Suppl. 2), S253-S259.
3. Beaugerie, L., Carrat, F., Bouvier, A. M., Brousse, N., & Carbonnel, F. (2008). Excess risk of lymphoproliferative disorders (LPD) in inflammatory bowel diseases (IBD): Interim results of the CESAME Cohort (Abstract # 818). Paper presented at the 2008 Annual Digestive Disease Week Meeting, San Diego, CA.
4. Best, W. R., Becktel, J. M., Singleton, J. W., & Kern, F. (1976). Development of a Crohn's disease activity index. Gastroenterology, 70(3), 439-444.
5. Bodger, K. (2002). Cost of illness of Crohn's disease. Pharmacoeconomics, 20(10), 639-652.
6. Büning, C., & Lochs, H. (2006). Conventional therapy for Crohn's disease. World Journal of Gastroenterology, 12(30), 4794-4806.
7. Centers for Disease Control and Prevention. (2000). Measuring healthy days. Atlanta, GA: Author.
8. Centers for Disease Control and Prevention. (2007). Inflammatory bowel disease. Retrieved July 20, 2008, from http://www.cdc. gov/nccdphp/dach/ibd.htm
9. Certolizumab [prescribing information]. (2008). Bridgewater, NJ: Enzon Pharmaceuticals, Inc., Retrieved August 15, 2008, from http://www.cimzia.com/pi. aspx
10. Feagan, B. G., Reinisch, W., Rutgeerts, P., Sandborn, W. J., Yan, S., Eisenberg, D., et al. (2007). The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. American Journal of Gastroenterology, 102, 794-802.
11. Feagan, B. G., Sandborn, W. J., Hass, S., Niecko, T., & White, J. (2007). Health-related quality of life during natalizumab maintenance therapy for Crohn's disease. American Journal of Gastroenterology, 102(12), 2737-12346
12. Gordon, F. H., Lai, C. W., Hamilton, M. I., Allison, M. C., Srivastava, E. D., Fouweather, M. G., et al. (2001). A randomized placebocontrolled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gastroenterology, 12, 268-274.
13. Gregor, J. C., McDonald, J. W. D., Klar, N., Wall, R., Atkinson, K., Limba, B., et al. (1997). An evaluation of utility measurement in Crohn's disease. Inflammatory Bowel Diseases, 3, 265-276.
14. Hanauer, S. (2006). Inflammatory bowel disease: Epidemiology, pathogenesis and therapeutic opportunities. Inflammatory Bowel Diseases, 12(Suppl. 1), S3-S9.
15. Hanauer, S. B., Feagan, B. G., Lichtenstein, G. R., Mayer, L. F., Schreiber, S., Columbel, J. F., et al. (2002). Maintenance infliximab for Crohn's disease: The ACCENT I randomized trial. Lancet, 359, 1541-1549.
16. Hanauer, S. B., & Sandborn, W. (2001). Management of Crohn's disease in adults: Practice parameters committee of the American College of Gastroenterology. American Journal of Gastroenterology, 96(3), 635-643.
17. Hanauer, S. B., Sandborn, W. J., Rutgeerts, P., Fedorack, R. N., Lukas, M., MacInstosh, D., et al. (2006). Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology, 130(2), 323-333.
18. Irvine, E. J. (1997). Quality of life issues in patients with inflammatory bowel disease. American Journal of Gastroenterology, 92, 18S-24S.
19. Irvine, E. J., Feagan, B., Ronchon, J., Archambault, A., Fedorack, R.N., Groll, A., et al. (1994). Quality of life: A valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease: Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology, 106, 287-296.
20. Johnson, F. R., Ozdemir, S., Mansfield, C., Hass, S., Miller, D. W., Siegel, C. A., et al. (2007). Crohn's disease patients' risk-benefit preferences: Serious adverse event risks versus treatment efficacy. Gastroenterology, 133(3), 769-779.
21. Juillerat, P., Pittet, V., Felley, C., Mottet, C., Froehlich, F., Vader, J. P., et al. (2007). Drug safety in Crohn's disease therapy. Digestion, 76(2), 161-168.
22. Kandiel, A., Fraser, A. G., Korelitz, B. I., Brensinger, C., & Lewis, J. D. (2005). Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut, 54(8), 1121-1125.
23. Katz, J. A. (2007). Management of inflammatory bowel disease in adults. Journal of Digestive Diseases, 8(2), 65-71.
24. Lichtenstein, G. R., Feagan, B. G., Cohen, R. D., Salzberg, B. A., Diamond, R. H., Chen, D. M., et al. (2006). Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clinical Gastroenterology & Hepatology, 4(5), 621-630.
25. Loftus, E. V., & Sandborn, W. J. (2003). Epidemiology of inflammatory bowel disease. Gastroenterology Clinics of North America, 31, 1-20.
26. McHorney, C. A., Ware, J. E., & Raczek, A. E. (1993). The MOS- 36 item short form health survey (SF-36), II: Psychometric and clinical tests of validity in measuring physical and mental health constructs. Medical Care, 31, 247-263.
27. Metcalf, C. (2002). Crohn's disease: An overview. Nursing Standard, 16(31), 45-52; quiz 54-55.
28. Nielsen, O. H., & Munck, L. K. (2007). Drug insight: Aminosalicylates for the treatment of IBD. Nature Clinical Practice Gastroenterology & Hepatology, 4(3), 160-170.
29. Plante, M. L. (2004). Crohn's disease: Achieving optimum health status. ADVANCE for Nurse Practitioners, 12(5), 28-35.
30. Prefontaine, E., Sutherland, L. R., Macdonald, J. K., & Cepoiu, M. (2008). Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database of Systematic Reviews, 1, CD000067.
31. Remicade [prescribing information]. Malvern, PA: Centocor Inc. Retrieved August 15 2008, from 2008 :http://www.remicade. com/remicade/assets/HCP-PPI.pdf
32. Rutgeerts, P. J. (2001). Review article: The limitations of corticosteroid therapy in Crohn's disease. Alimentary Pharmacology & Therapeutics, 15(10), 1515-1525.
33. Rutgeerts, P., Lofberg, R., Malchow, H., Lamers, C., Olaison, G., Jewell, D., et al. (1994). A comparison of budesonide with prednisolone for active Crohn's disease. New England Journal of Medicine, 331(13), 842-845. (Pubitemid 24289711)
34. Ruthruff, B. (2007). Clinical review of Crohn's disease. Journal of the American Academy of Nurse Practitioners, 19(8), 392-397.
35. Sandborn, W. J., Colombel, J. F., Enns, R., Feagan, B. G., Hanauer, S. B., Lawrance, I. C., et al. (2005). Natalizumab induction and maintenance therapy for Crohn's disease: The ENACT-1 and ENACT-2 trials. New England Journal of Medicine, 353, 1912-1925.
36. Sandborn, W. J., Feagan, B. G., Stoinov, S., Honiball, P. J., Rutgeerts, P., Mason, D., et al. (2007). Certolizumab pegol for the treatment of Crohn's disease. New England Journal of Medicine, 357(3), 228-238.
37. Sandborn, W. J., Sutherland, L., Pearson, D., May, G., Modigliani, R., & Prantera, C. (2000). Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Systematic Reviews, 2, CD000545.
38. Smith, G. D., Watson, R., Roger, D., McRorie, E., Hurst, N., Luman, W., et al. (2002). Impact of a nurse-led counseling service on quality of life in patients with inflammatory bowel disease. Journal of Advanced Nursing, 38(2), 152-160.
39. Solomon, M. J. (1996). Fistulae and abscesses in symptomatic perianal Crohn's disease. International Journal of Colorectal Disease, 11(5), 222-226.
40. Targan, S. R., Feagan, B. G., Fedorak, R. N., Lashner, B. A., Panaccione, R., Present, D. H., et al. (2007). Natalizumab for the treatment of active Crohn's disease: Results of the ENCORE trial. Gastroenterology, 132, 1672-1683. (Pubitemid 46695722)
41. Targan, S. R., Hanauer, S. B., van Deventer, S. J., Mayer, L., Present, D. H., Braakman, T., et al. (1997). A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease: Crohn's Disease cA2 Study Group. New England Journal of Medicine, 337, 1029-1035.
42. Tysabri [prescribing information]. (2008). Dublin, Ireland: Elan Pharmaceuticals, Inc. Retrieved August 15, 2008, from http://www.tysabri.com/ tysbProject/tysb.portal
43. Ware, J. E., & Sherbourne, C. D. (1992). The MOS SF-36 short form health survey (SF-36): Conceptual framework and item selection. Medical Care, 30, 473-481.
44. Wolters, F. L., Russel, M. G., & Stockbrugger, R. W. (2004). Systematic review: Has disease outcome in Crohn's disease changed during the last four decades? Alimentary Pharmacology & Therapeutics, 20(5), 483-496.
45. Zutshi, M., Hull, T. L., & Hammel, J. (2007). Crohn's disease: A patient's perspective. International Journal of Colorectal Disease, 22(12), 1437-1444.